跳至主要内容
临床试验/EUCTR2009-009155-37-FR
EUCTR2009-009155-37-FR进行中(未招募)1 期

Evaluation of the impact of physical reconditioning associated with specific nutritional supplementation in obese patients suffering of metabolic syndrome. - OBEFITT

CHU-HOPITAUX DE ROUE0 个研究点目标入组 80 人开始时间: 2010年4月30日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Suffering of obesity (BMI> 30 kg.m-2) with a maximal weight of 135 kg
  • Suffering of metabolic syndrome (NCEP definition)
  • Hospitalized or followed in consultation
  • Aged of 18 to 45 year old
  • Not having participated to other clinical studies during the last 30 days before pre-inclusion consultation
  • Affiliated to a national insurance scheme
  • Having a social insurance
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Asthma, chronic respiratory failure, obstructive chronic bronchitis
  • Current or recent Pneumothorax, recent pleural draining or biopsy, current hemoptysia, untreated / in course of treatment active tuberculosis
  • Coronaropathy, myocardiopathy, myocarditis, unstable cardiac failure, ventricular rythm disorders
  • Severe Anaemia
  • Severe inferior members Arteritis
  • Incapacity of walking or pedaling
  • Severe renal failure (Creatinine Clearance < ou = 30 mL/min)
  • Severe Sepsis
  • Psychiatric Troubles (DSM IV criteria) such as schizophrenia, others psychoses or major depressive non treated syndromes
  • Severe or non treated eating disorders implicated in obesity (compulsive access, bulimia)
  • Patients under guardianship or under guardianship
  • Women in age of procreation without means of effective contraception
  • Pregnant or breast-feeding women
  • Taking of medicines such as : proteinated powder (Protifar®, SP95®), Orlistat (Xenical®, Alli®), Exenatide (Byetta®), Sitagliptine (Januvia®, Xelevia®), Vildapgliptine (Galvus®), association Sitagliptine-Metformine (Janumet®), association Vildagliptine-Metformine (Eucreas®), Tadalafil (Cialis®), Sildénafil (Viagra®)
  • Drug addiction to opiates in the last six months
  • Abuse of alcohol and other toxic matters
  • Infection by HIV, viral hepatitis B and viral hepatitis C
  • Active addiction to smoking in more than 8 cigarettes a day
  • Understanding badly spoken or written French
  • Realization, in 2 in 3 days preceding the DEXA exam, of a bone scintigraphy or a digestive tract's radiological examination with product of contrast of type baryte.

研究者

发起方
CHU-HOPITAUX DE ROUE

相似试验